Skip to content

US · NMTC · MEDICAL - DEVICES

NeuroOne Medical Technologies Corporation (NMTC) intrinsic value and stock valuation

$0.65as of 2026-11-21 · Mkt cap 14.36M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NeuroOne Medical Technologies Corporation DCF and intrinsic value

InvestorsCraft values NMTC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NMTC’s statements →

NeuroOne Medical Technologies Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Eden Prairie, MN 55344 nmtc1.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$12.1M+44.4% 5y CAGRd
20112025
Net income
-$-3.61M
20112025
Free cash flow
-$-2.92M
20112025
Total equity
$7.07M+27.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$12.1M$3.45M$1.95M$170K$180K
Operating income-$-4.23M-$-11.89M-$-11.96M-$-10.03M-$-10.22M
Net income-$-3.61M-$-12.32M-$-11.86M-$-10M-$-9.95M
EPSd-$-539.61K-$-2.76M-$-3.93M-$-3.75M-$-5.59M
Operating cash flow-$-2.84M-$-11.01M-$-12.89M-$-7.52M-$-8.6M
Capital expenditure-$-80K-$-120K-$-380K-$-280K-$-70K
Free cash flow-$-2.92M-$-11.13M-$-13.27M-$-7.79M-$-8.67M
Total assets$10.8M$5.37M$8.1M$12.8M$7.94M
Total debt$270K$260K$180K$200K$320K
Net debt-$-6.3M-$-1.2M-$-5.14M-$-7.96M-$-6.59M
Total equity$7.07M$820K$6.25M$9.6M$6.55M
Cash and short-term investments$6.57M$1.46M$5.32M$11.1M$6.9M
Income statement
20252024202320222021
Revenue$12.1M$3.45M$1.95M$170K$180K
Cost of revenue$3.96M$2.37M$1.5M$240K$280K
Gross profit$8.14M$1.08M$460K-$-70K-$-100K
Research and development expenses$4.98M$5.07M$6.94M$4.93M$3.93M
Selling, general and administrative expenses$7.38M$7.9M$6.93M$6.98M$6.26M
Other expenses$0.00$0.00-$-1.46M-$-1.95M-$-60K
Operating expenses$12.4M$13M$12.4M$9.96M$10.1M
Cost and expenses$16.3M$15.3M$13.9M$10.2M$10.4M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$330K$230K$0.00$0.00$0.00
Depreciation and amortization$260K$250K$200K$120K$150K
Ebitda-$-3.01M-$-11.84M-$-11.66M-$-9.88M-$-9.8M
Operating income-$-4.23M-$-11.89M-$-11.96M-$-10.03M-$-10.22M
Total other income/expenses, net$620K-$-430K$100K$30K$270K
Income before tax-$-3.61M-$-12.32M-$-11.86M-$-10M-$-9.95M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-3.61M-$-12.32M-$-11.86M-$-10M-$-9.95M
Weighted average shares outstanding$6.69M$4.46M$3.02M$2.67M$1.78M
Weighted average diluted shares outstanding$6.69M$4.46M$3.02M$2.67M$1.78M
Balance sheet
20252024202320222021
Cash and short-term investments$6.57M$1.46M$5.32M$11.1M$6.9M
Net receivables$1.26M$180K$0.00$30K$50K
Inventory$2.23M$2.64M$1.73M$700K$100K
Total current assets$10.2M$4.63M$7.31M$12.2M$7.29M
Property, plant and equipment, net$510K$670K$690K$530K$510K
Goodwill and intangible assets$40K$70K$90K$110K$130K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$560K$740K$780K$650K$650K
Total assets$10.8M$5.37M$8.1M$12.8M$7.94M
Accounts payable$1.01M$1.03M$690K$930K$530K
Short-term debt$120K$70K$130K$80K$110K
Deferred revenue$0.00$0.00$0.00$1.46M$10K
Total current liabilities$2.3M$2.21M$1.79M$3.1M$1.18M
Long-term debt$140K$190K$60K$120K$200K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.41M$2.33M$60K$120K$200K
Capital lease obligations$270K$260K$180K$200K$320K
Total liabilities$3.71M$4.55M$1.85M$3.22M$1.38M
Common stock$50K$30K$20K$20K$10K
Retained earnings-$-78.61M-$-75M-$-62.69M-$-50.83M-$-40.83M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$7.07M$820K$6.25M$9.6M$6.55M
Total investments$0.00$0.00$0.00$2.98M$0.00
Total debt$270K$260K$180K$200K$320K
Net debt-$-6.3M-$-1.2M-$-5.14M-$-7.96M-$-6.59M
Cash flow statement
20252024202320222021
Net income-$-3.61M-$-12.32M-$-11.86M-$-10M-$-9.95M
Depreciation and amortization$260K$250K$200K$120K$80K
Stock-based compensation$1.26M$1.34M$1.11M$950K$1.79M
Change in working capital-$-430K-$-950K-$-2.43M$1.21M-$-510K
Accounts receivable-$-1.09M-$-180K$30K$20K-$-50K
Inventory$400K-$-910K-$-1.02M-$-610K-$-100K
Accounts payable$240K$70K-$-250K$520K-$-350K
Net cash provided by operating activities-$-2.84M-$-11.01M-$-12.89M-$-7.52M-$-8.6M
Investments in property, plant and equipment-$-80K-$-120K-$-380K-$-280K-$-70K
Acquisitions, net$0.00$0.00$0.00$2.97M$0.00
Net cash used for investing activities-$-80K-$-120K$2.65M-$-3.24M-$-70K
Common stock issued$9.68M$7.43M$8.59M$13.4M$8.83M
Common stock repurchased-$-120K-$-80K-$-120K$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$8.03M$7.27M$7.4M$12M$11.5M
Net change in cash$5.11M-$-3.86M-$-2.84M$1.26M$2.86M
Cash at end of period$6.57M$1.46M$5.32M$8.16M$6.9M
Operating cash flow-$-2.84M-$-11.01M-$-12.89M-$-7.52M-$-8.6M
Capital expenditure-$-80K-$-120K-$-380K-$-280K-$-70K
Free cash flow-$-2.92M-$-11.13M-$-13.27M-$-7.79M-$-8.67M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NeuroOne Medical Technologies Corporation

        NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.

        CEO
        David A. Rosa
        Employees
        18
        Beta
        0.64

        Explore

        Frequently asked questions

        What is the intrinsic value of NeuroOne Medical Technologies Corporation (NMTC)?

        InvestorsCraft does not currently publish an intrinsic value for NMTC. How the IC value is calculated.

        Is NMTC undervalued?

        InvestorsCraft does not publish an undervaluation signal for NMTC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.